636
Participants
Start Date
July 31, 2011
Primary Completion Date
July 31, 2015
Study Completion Date
July 31, 2015
ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)
18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
Placebo
weekly, intramuscular, until disease progression or toxicity.
Best Supportive Care
treatment of disease-related symptoms throughout the study.
Memorial Sloan-Kettering Cancer Center, New York
University of Maryland Greenbaum Cancer Center, Baltimore
China Medicine University Hospital, Taichung
Wayne State University School of Medicine, Dept Oncology, Detroit
Catherine Frenette, La Jolla
Southern California Research Center, Coronado
5th Fl, Inpatient Bldg, No. 8,, Fengtai Distrcit
5th Floor, Medical Building, No. 1018 Huguang Rd, Changchun
No. 193, Lianhe Rd, Shahekou Dist., Dalian
3rd Floor, Medicine Building, No. 150 Haping Rd, Harbin
Oncology, 185 Road Juqian Street, Changzhou
Oncology, No. 678, Furong Rd, Hefei
A ward of Oncology-287 Changhuai Rd, Bengbu
No. 156 North Road of West Second Ring, Gulou District
13th Floor, Internal Medicine Building, No. 29 Gaotanyan Main St., Chongqing
15th Floor, In-patient Building (East), No. 651 Dongfeng East Road, Guangzhou
5th Fl, Inpatient Bldg, No. 71, Heti Rd, Qingxiu Disttrict
Floor 7, 3rd Inpatient Building No. 37, Guoxue Xiang, Chengdu
No. 596, Xinsi Rd., Baqiao Dist., Xi'an
University of Alabama, Birmingham
Stanford University, Palo Alto
University of California at San Diego Moores Cancer Center, San Diego
Pacific Medical Center, San Francisco
Piedmont Research Institute, Atlanta
University of Hawaii, Honolulu
Johns Hopkins University Hospital, Baltimore
University of Minnesota Cancer Center, Minneapolis
Nebraska Hem-Onc, Lincoln
University of Oregon, Portland
Drexel University, Philadelphia
University of Pennsylvania Abramson Cancer Center, Philadelphia
UPMC Cancer Centers, Pittsburgh
UT Southwestern, Dallas
Michael E. DeBakey VA Medical Center, Houston
University of Washington, Seattle
The First Hospital of Medical University Of Anhui, Hefei
The Chinese people's liberation army 81 hospital, Nanjing
Bldg No. 5, 3rd Floor, Dongan Rd, Shanghai
"Istituto Tumori Giovanni Paolo II", Bari
Policlinico S. Orsola-Malpighi, Bologna
Azienda Ospedaliera Niguarda Cà Granda, Milan
Fondazione Centro San Raffaele del Monte Tabor, Milan
"Fondazione IRCCs Ca Granda Ospedale Maggiore Policlinico", Milan
Policlinico di Monza, Monza
Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples
Azienda Ospedaliera di Padova, Padua
Azienda Ospedaliera San Camillo Forlanini, Roma
Instituto Nazionale pler le Malattie Infettive, Rome
Asan Medical Center, Seoul
Korea University Anam Hospital, Seoul
Samsung Medical Center, Seoul
Seoul St. Mary's Hospital, Seoul
Severance Hospital, Seoul
CGMHCY, Chiayi City
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
Chang Gung Medical Foundation-Kaohsiung, Kaohsiung County
CMMC-LY, Tainan City
CMMC-YK, Tainan City
National Cheng Kung University Hospital, Tainan City
Mackay Memorial Hospital-Taipei Branch, Taipei
Northern Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Chang Gung Medical Foundation-Linkou, Taoyuan
Clatterbridge Cancer Center, Bebington
University Hospitals Birmingham NHS Foundation Trust, Birmingham
Hammersmith Hospital, London
King's College Hospital, London
Royal Free Hospital, London
St. Bartholomew's Hospital, London
The Royal Marsden Hospital, London
Christie NHS Trust, Manchester
Nottingham University Hospital, Nottingham
Royal Marsden, Sutton
Lead Sponsor
Polaris Group
INDUSTRY